Groowe Groowe / Newsroom / MRK
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

MRK News

Merck & Co., Inc.

EU and USA Veterinary Drug Development Training Course: Pharmaceutical, Pharmacological, Toxicological and Clinical Investigations and Regulatory Management (ONLINE EVENT: June 15th - June 18th, 2026)

globenewswire.com
MRK VCTR

MilliporeSigma Launches 2026 Global Curiosity Cube(TM) Tour, Bringing STEM Learning to Students

accessnewswire.com
MRK

Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting

globenewswire.com
MRK JNJ

Kelun-Biotech Announces Results from the SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in Gynecologic Oncology Presented at 2026 SGO USA - English APAC - Traditional Chinese APAC - English

prnewswire.com
MRK

Florida Cancer Specialists & Research Institute Contributes to Milestone that Expands Treatment Options For Patients With Recurrent Ovarian Cancer

prnewswire.com
MRK

Francois Schramek Promoted to Partner at Manhattan West

prnewswire.com
AI AMN GM LMT NVDA GOOG MSFT SPCE RKLB GD BA AMD INTC META CRWD PLTR AN DD HON RTX IBM AMZN TSLA XOM CVX UNH BMY PFE MRK JNJ LLY GILD REGN BIIB AMGN AZN NVO SNY TEVA BABA JD NTES BIDU IQ VIPS BZUN HTHT MELI BBD BB ERIC NOK QCOM MU ADSK CRM GOOGL

1 Day 2024 EU AI Act Legislative Changes and Potential Impact on Healthcare Webinar: (ONLINE EVENT: June 23, 2026)

globenewswire.com
MRK

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

businesswire.com
MRK

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

businesswire.com
MRK

Cell Therapy Technology Market Research and Global Forecast Report 2025-2030: Rising Chronic Disease Burden and CRISPR-Driven Gene Editing Innovations Driving Growth

globenewswire.com
TMO DHR MRK